摘要
目的探讨冠心病房颤患者采用替格瑞洛联合经皮冠状动脉介入(PCI)治疗对心功能及炎症因子的影响。方法将我院2019年12月至2021月12月收治的94例冠心病房颤者随机分为对照组和观察组,各47例。入组患者均给予PCI干预,对照组围术期给予氯吡格雷干预,观察组联合替格瑞洛干预,两组均治疗3个月后评定疗效,并测量患者心功能、炎性因子水平,统计主要不良心血管事件(MACE)及药物不良反应发生率。结果两组治疗3个月后LVEF、CI及SV高于治疗前,LVESD、LVEDD低于治疗前;治疗后观察组LVEF、CI及SV高于对照组,LVESD、LVEDD低于对照组,差异具有统计意义(P<0.05);治疗后,两组CRP、IL-6与TNF-α低于治疗前,且观察组低于对照组,差异具有统计意义(P<0.05);观察组治疗期间MACE发生率低于对照组(P<0.05);两组用药期间肝肾异常、恶心呕吐、腹泻便秘等不良反应总发生率无统计意义(P>0.05)。结论冠心病房颤患者采用替格瑞洛联合PCI治疗可改善患者心功能,降低炎性因子水平与MACE发生率,且药物安全性较高。
Objective To investigate the effect of ticagrelor combined with percutaneous coronary intervention(PCI)on cardiac function and inflammatory factors in patients with coronary heart disease and atrial fibrillation.Methods A total of 94 patients with coronary heart disease and atrial fibrillation admitted to our hospital from December 2019 to December 2021 were randomly divided into a control group and an observation group,with 47 cases in each.The enrolled patients were all given PCI intervention,the control group was given clopidogrel intervention in the perioperative period,and the observation group was combined with ticagrelor intervention.After 3 months of treatment,the curative effect was evaluated in both groups,and the cardiac function and inflammatory factor levels were measured.The incidence of major adverse cardiovascular events(MACE)and adverse drug reactions were counted.Results After 3 months of treatment,LVEF,CI and SV in the two groups were higher than those before treatment,while LVESD and LVEDD were lower than those before treatment.Statistical significance(P<0.05);after treatment,CRP,IL-6 and TNF-αin the two groups were lower than before treatment,and the observation group was lower than the control group,the difference was statistically significant(P<0.05);MACE in the observation group during the treatment The incidence rate was lower than that in the control group(P<0.05);the total incidence of adverse reactions such as abnormal liver and kidney,nausea and vomiting,diarrhea and constipation during the two groups was not statistically significant(P>0.05).Conclusion Ticagrelor combined with PCI in patients with coronary heart disease and atrial fibrillation can improve cardiac function,reduce the level of inflammatory factors and the incidence of MACE,and the drug is safe.
作者
张云翔
董凯丽
丁水印
ZHANG Yun-xiang;DONG Kai-li;DING Shui-yin(Departments of Cardiovascular Medicine in Zhumadian Central Hospital,Zhumadian 463000,Henan Province,China)
出处
《罕少疾病杂志》
2023年第1期41-42,共2页
Journal of Rare and Uncommon Diseases
关键词
替格瑞洛
经皮冠状动脉介入
冠心病房颤
心功能
炎性因子
Ticagrelor
Percutaneous Coronary Intervention
Coronary Heart Disease Atrial Fibrillation
Cardiac Function
Inflammatory Factors
